Morgan Stanley Downgrades Prelude Therapeutics (PRLD) to Underweight

December 19, 2023 3:12 AM EST Send to a Friend
Morgan Stanley analyst Jeffrey Hung downgraded Prelude Therapeutics (NASDAQ: PRLD) from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login